These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 6409375)
21. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Csanda E; Tárczy M Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143 [TBL] [Abstract][Full Text] [Related]
22. Practical therapeutics: advances in the management of Parkinson's disease. Adam AM East Afr Med J; 1985 Feb; 62(2):143-6. PubMed ID: 3930202 [No Abstract] [Full Text] [Related]
23. Current controversies in the use of selegiline hydrochloride. Lees AJ J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602 [TBL] [Abstract][Full Text] [Related]
24. Deprenyl in Parkinson's disease. Korczyn AD; Nisipeanu P Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617 [No Abstract] [Full Text] [Related]
25. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. Streifler M; Rabey MJ J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992 [TBL] [Abstract][Full Text] [Related]
26. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Tetrud JW; Langston JW Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843 [TBL] [Abstract][Full Text] [Related]
27. Adjuvant drugs in the treatment of on-off phenomena in Parkinson's disease. Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Bihari K Adv Neurol; 1984; 40():549-56. PubMed ID: 6421113 [No Abstract] [Full Text] [Related]
28. Clinical and pharmacological problems of deprenyl (selegiline) treatment in Parkinson's disease. Stern GM; Lees AJ; Hardie RJ; Sandler M Acta Neurol Scand Suppl; 1983; 95():113-6. PubMed ID: 6428142 [TBL] [Abstract][Full Text] [Related]
29. Recent observations on the clinical pharmacology of (-)deprenyl. Stern GM; Lees AJ; Sandler M J Neural Transm; 1978; 43(3-4):245-51. PubMed ID: 745017 [No Abstract] [Full Text] [Related]
30. Deprenyl and levodopa and Parkinson's disease progression. Fowler JS; Fazzini E; Volkow ND Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616 [No Abstract] [Full Text] [Related]
31. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Birkmayer W; Riederer P Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111 [No Abstract] [Full Text] [Related]
32. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol; 1998 Mar; 43(3):318-25. PubMed ID: 9506548 [TBL] [Abstract][Full Text] [Related]
33. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Fowler JS; Volkow ND; Logan J; Wang GJ; MacGregor RR; Schyler D; Wolf AP; Pappas N; Alexoff D; Shea C Synapse; 1994 Oct; 18(2):86-93. PubMed ID: 7839316 [TBL] [Abstract][Full Text] [Related]
34. New approaches in the use of selegiline for the treatment of Parkinson's disease. Lees AJ; Frankel J; Eatough V; Stern GM Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719 [TBL] [Abstract][Full Text] [Related]
35. 2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]. Reynolds GP; Riederer P; Sandler M Biochem Soc Trans; 1979 Feb; 7(1):143-5. PubMed ID: 437259 [No Abstract] [Full Text] [Related]
36. Clinical and pharmacological aspects of (-)-deprenyl treatment in Parkinson's disease. Stern GM; Lees AJ; Hardie R; Sandler M Mod Probl Pharmacopsychiatry; 1983; 19():215-9. PubMed ID: 6408407 [No Abstract] [Full Text] [Related]
37. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A; Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107 [TBL] [Abstract][Full Text] [Related]
38. Observations made with L-deprenil (Jumex) in the long-term treatment of outpatients with Parkinson's syndrome. Gyimóti G; Csanaky A; Leposa D Ther Hung; 1983; 31(1):26-30. PubMed ID: 6443750 [No Abstract] [Full Text] [Related]